DOA
CRL icon

D'Orazio & Associates’s Charles River Laboratories CRL Stock Holding History

D'Orazio & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed -$1K – 229
2021
Q3 		$1K Buy
+2
New +$831 ﹤0.01% 720

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D'Orazio & Associates's CRL Position: Q4 2021 in Review

D'Orazio & Associates sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 2 shares — an estimated $1K sold.

D'Orazio & Associates first reported a position in CRL in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

  • D'Orazio & Associates reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
  • D'Orazio & Associates sold 2 Charles River Laboratories shares in Q4 2021, an estimated $1K.
  • D'Orazio & Associates first reported a position in Charles River Laboratories in Q3 2021 and held it in 1 quarter.
  • D'Orazio & Associates's Charles River Laboratories position peaked at $1K in Q3 2021.
  • 707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.